Immune response in patients with newly diagnosed glioblastoma multiforme treated with intranodal autologous tumor lysate-dendritic cell vaccination after radiation chemotherapy

Journal of Immunotherapy

Volumn 34, Issue 4, 2011, Pages 382-389

  Fadul, Camilo E ^a,b,c   Fisher, Jan L ^b   Hampton, Thomas H ^a,b   Lallana, Enrico C ^a,c   Li, Zhongze ^d   Gui, Jiang ^b,d   Szczepiorkowski, Zbigniew M ^c,e   Tosteson, Tor D ^d   Rhodes, C Harker ^e   Wishart, Heather A ^f,g   Lewis, Lionel D ^c,h   Ernstoff, Marc S ^a,b  

^a DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^b Medical Oncology Immunotherapy Program   (United States)

^c NORRIS COTTON CANCER CENTER   (United States)

^d Section of Epidemiology and Biostatistics   (United States)

^e Department of Pathology ^*  (United States)

^f Departments of Radiology   (United States)

^g Brain Imaging Laboratory   (United States)

^h Section of Clinical Pharmacology   (United States)

Author keywords

dendritic cells; glioblastoma; immune response; vaccine

Indexed keywords

DENDRITIC CELL VACCINE; TEMOZOLOMIDE;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER RADIOTHERAPY; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CELL LYSATE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GLIOBLASTOMA; HUMAN; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MALE; NECK PAIN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIATION DOSE; SKIN MANIFESTATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; CANCER VACCINES; COMBINED MODALITY THERAPY; DACARBAZINE; DENDRITIC CELLS; EPITOPES; FEMALE; GLIOBLASTOMA; HUMANS; IMMUNITY, CELLULAR; MALE; MIDDLE AGED; RADIOTHERAPY; RESEARCH DESIGN; SURVIVAL ANALYSIS; T-LYMPHOCYTES; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 79955591522     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/CJI.0b013e318215e300     Document Type: Article

References (45)

1. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987-996. (Pubitemid 40349501)
2. Weller M, Fontana A. The failure of current immunotherapy for malignant glioma. Tumor-derived. Brain Res Brain Res Rev. 1995;21:128-151.
3. Rutkowski S, De Vleeschouwer S, Kaempgen E, et al. Surgery and adjuvant dendritic cell-based tumour vaccination for patients with relapsed malignant glioma, a feasibility study. Br J Cancer. 2004;91:1656-1662. (Pubitemid 39546137)
4. Liau LM, Prins RM, Kiertscher SM, et al. Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment. Clin Cancer Res. 2005;11:5515-5525. (Pubitemid 41060828)
5. Yamanaka R, Homma J, Yajima N, et al. Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: results of a clinical phase I/II trial. Clin Cancer Res. 2005;11: 4160-4167. (Pubitemid 40791581)
6. De Vleeschouwer S, Fieuws S, Rutkowski S, et al. Postoperative adjuvant dendritic cell-based immunotherapy in patients with relapsed glioblastoma multiforme. Clin Cancer Res. 2008;14:3098-3104.
7. Walker DG, Laherty R, Tomlinson FH, et al. Results of a phase I dendritic cell vaccine trial for malignant astrocytoma: potential interaction with adjuvant chemotherapy. J Clin Neurosci. 2008;15:114-121. (Pubitemid 50017630)
8. Su YB, Sohn S, Krown SE, et al. Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications. J Clin Oncol. 2004;22:610-616. (Pubitemid 41095063)
9. Hughes MA, Parisi M, Grossman S, et al. Primary brain tumors treated with steroids and radiotherapy: low CD4 counts and risk of infection. Int J Radiat Oncol Biol Phys. 2005;62:1423-1426. (Pubitemid 40982064)
10. Kalinski P, Schuitemaker JH, Hilkens CM, et al. Prostaglandin E2 induces the final maturation of IL-12-deficient CD1a+CD83+ dendritic cells: the levels of IL-12 are determined during the final dendritic cell maturation and are resistant to further modulation. J Immunol. 1998;161: 2804-2809. (Pubitemid 28425700)
11. Rieser C, Bock G, Klocker H, et al. Prostaglandin E2 and tumor necrosis factor alpha cooperate to activate human dendritic cells: synergistic activation of interleukin 12 production. J Exp Med. 1997;186:1603-1608. (Pubitemid 27479821)
12. Bedrosian I, Mick R, Xu S, et al. Intranodal administration of peptide-pulsed mature dendritic cell vaccines results in superior CD8+ T-cell function in melanoma patients. J Clin Oncol. 2003;21:3826-3835. (Pubitemid 46606238)
13. Lambert LA, Gibson GR, Maloney M, et al. Intranodal immunization with tumor lysate-pulsed dendritic cells enhances protective antitumor immunity. Cancer Res. 2001;61: 641-646. (Pubitemid 32128627)
14. Weller RO, Galea I, Carare RO, et al. Pathophysiology of the lymphatic drainage of the central nervous system: implications for pathogenesis and therapy of multiple sclerosis. Pathophysiology. 2010;17:295-306.
15. Walter BA, Valera VA, Takahashi S, et al. The olfactory route for cerebrospinal fluid drainage into the peripheral lymphatic system. Neuropathol Appl Neurobiol. 2006;32:388-396. (Pubitemid 44015580)
16. Goldmann J, Kwidzinski E, Brandt C, et al. T cells traffic from brain to cervical lymph nodes via the cribroid plate and the nasal mucosa. J Leukoc Biol. 2006;80:797-801. (Pubitemid 44835898)
17. Hatterer E, Davoust N, Didier-Bazes M, et al. How to drain without lymphatics? Dendritic cells migrate from the cerebrospinal fluid to the B-cell follicles of cervical lymph nodes. Blood. 2006;107:806-812. (Pubitemid 43076409)
18. Karman J, Ling C, Sandor M, et al. Initiation of immune responses in brain is promoted by local dendritic cells. J Immunol. 2004;173:2353-2361. (Pubitemid 39063091)
19. Wheeler CJ, Black KL, Liu G, et al. Vaccination elicits correlated immune and clinical responses in glioblastoma multiforme patients. Cancer Res. 2008;68:5955-5964.
20. Yu JS, Liu G, Ying H, et al. Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic Tcells in patients with malignant glioma. Cancer Res. 2004;64: 4973-4979. (Pubitemid 38924545)
21. Schwaab T, Schwarzer A, Wolf B, et al. Clinical and immunologic effects of intranodal autologous tumor lysatedendritic cell vaccine with Aldesleukin (Interleukin 2) and IFN-(alpha)2a therapy in metastatic renal cell carcinoma patients. Clin Cancer Res. 2009;15:4986-4992.
22. Ernstoff MS, Crocenzi TS, Seigne JD, et al. Developing a rational tumor vaccine therapy for renal cell carcinoma: immune yin and yang. Clin Cancer Res. 2007;13:733s-740s.
23. Schwaab T, Fisher JL, Meehan KR, et al. Dye dilution proliferation assay: application of the DDPA to identify tumor-specific T cell precursor frequencies in clinical trials. Immunol Invest. 2007;36:649-664.
24. Givan AL, Fisher JL, Waugh MG, et al. Use of cell-tracking dyes to determine proliferation precursor frequencies of antigen-specific T cells. Methods Mol Biol. 2004;263:109-124.
25. Bercovici N, Givan AL, Waugh MG, et al. Multiparameter precursor analysis of T-cell responses to antigen. J Immunol Methods. 2003;276:5-17. (Pubitemid 36513834)
26. Givan AL, Fisher JL, Waugh M, et al. A flow cytometric method to estimate the precursor frequencies of cells proliferating in response to specific antigens. J Immunol Methods. 1999;230:99-112.
27. Janetzki S, Panageas KS, Ben-Porat L, et al. Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI). Cancer Immunol Immunother. 2008; 57:303-315. (Pubitemid 350295382)
28. Macdonald DR, Cascino TL, Schold SC Jr, et al. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol. 1990;8:1277-1280. (Pubitemid 20195640)
29. Yu JS, Wheeler CJ, Zeltzer PM, et al. Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration. Cancer Res. 2001;61:842-847. (Pubitemid 32175145)
30. Ardon H, Van Gool S, Lopes IS, et al. Integration of autologous dendritic cell-based immunotherapy in the primary treatment for patients with newly diagnosed glioblastoma multiforme: a pilot study. J Neurooncol. 2010;99:261-272.
31. Cho DY, Lee HC, Lin SZ. Autologous dendritic cell-based immunotherapy for maligant gliomas-A phase II prospective randomized clinical trial. Neuro-oncology. 2009;11:882.
32. Heimberger AB, Abou-Ghazal M, Reina-Ortiz C, et al. Incidence and prognostic impact of FoxP3+ regulatory T cells in human gliomas. Clin Cancer Res. 2008;14:5166-5172.
33. Fecci PE, Mitchell DA, Whitesides JF, et al. Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. Cancer Res. 2006;66:3294-3302.
34. El Andaloussi A, Lesniak MS. An increase in CD4+CD25+FOXP3+ regulatory T cells in tumor-infiltrating lymphocytes of human glioblastoma multiforme. Neuro Oncol. 2006;8:234-243. (Pubitemid 46542648)
35. Sampson JH, Aldape KD, Gilbert MR, et al. Temozolomide as a vaccine adjuvant in GBM. J Clin Oncol (Meeting Abstracts). 2007;25:2020.
36. Chiba Y, Hashimoto N, Tsuboi A, et al. Effects of concomitant temozolomide and radiation therapies on WT1-specific T-cells in malignant glioma. Jpn J Clin Oncol. 2010;40:395-403.
37. Heimberger AB, Sun W, Hussain SF, et al. Immunological responses in a patient with glioblastoma multiforme treated with sequential courses of temozolomide and immunotherapy: case study. Neuro Oncol. 2008;10:98-103. (Pubitemid 351250906)
38. Wheeler CJ, Das A, Liu G, et al. Clinical responsiveness of glioblastoma multiforme to chemotherapy after vaccination. Clin Cancer Res. 2004;10:5316-5326. (Pubitemid 39100466)
39. Banerjee DK, Dhodapkar MV, Matayeva E, et al. Expansion of FOXP3high regulatory T cells by human dendritic cells (DCs) in vitro and after injection of cytokine-matured DCs in myeloma patients. Blood. 2006;108:2655-2661.
40. Disis ML, Schiffman K, Gooley TA, et al. Delayed-type hypersensitivity response is a predictor of peripheral blood T-cell immunity after HER-2/neu peptide immunization. Clin Cancer Res. 2000;6:1347-1350. (Pubitemid 30226219)
41. Yamanaka R, Abe T, Yajima N, et al. Vaccination of recurrent glioma patients with tumour lysate-pulsed dendritic cells elicits immune responses: results of a clinical phase I/II trial. Br J Cancer. 2003;89:1172-1179. (Pubitemid 37363398)
42. Dancey JE, Dobbin KK, Groshen S, et al. Guidelines for the development and incorporation of biomarker studies in early clinical trials of novel agents. Clin Cancer Res. 2010;16:1745-1755.
43. + T cell production strongly influences tumor antigen recognition and age-dependent glioma mortality. J Immunol. 2003;171:4927-4933. (Pubitemid 37310617)
44. Kammula US, Marincola FM, Rosenberg SA. Real-time quantitative polymerase chain reaction assessment of immune reactivity in melanoma patients after tumor peptide vaccination. J Natl Cancer Inst. 2000;92:1336-1344. (Pubitemid 30660594)
45. Britten CM, Janetzki S, van der Burg SH, et al. Toward the harmonization of immune monitoring in clinical trials: quo vadis? Cancer Immunol Immunother. 2008;57:285-288. (Pubitemid 350295381)